We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

MICC:NYSEThe Magnum Ice Cream Company N.V. Analysis

Data as of 2026-07-01 - not real-time

$18.09

Latest Price

6/10Risk

Risk Level: Medium

Executive Summary

The stock is trading at $18.09, just shy of the calculated resistance of $18.16 and comfortably above the 20‑day SMA of $17.30, indicating a short‑term price ceiling. Technical momentum remains bullish with the 20‑day SMA above both the 50‑day ($15.93) and 200‑day ($15.87) averages, while the RSI sits at 64.9, suggesting strength but no imminent overbought condition. However, the MACD histogram is negative and the signal line is labeled “bearish,” hinting at a possible near‑term pullback. Volume is on an increasing trend and beta is low at 0.43, which tempers market‑wide volatility, though the 30‑day realized volatility of 31.8% signals sizable price swings. Fundamentally, the company carries a heavy debt load (Debt‑to‑Equity > 500) and its DCF fair value of $3.05 is far below the current price, making the equity appear overvalued with a modest upside‑downside metric of –3.1%. Revenue has contracted 4.1% YoY, but margins remain respectable (gross 34.6%, operating 10.1%) and free cash flow of $365 M supports ongoing operations. Recent news highlights solid Q1 sales growth and a reaffirmed outlook, while whispers of interest from Blackstone and CD&R add a potential acquisition catalyst. Balancing the strong brand portfolio against high leverage and a valuation gap suggests caution in the near term, but the long‑run narrative could improve if a strategic transaction materializes.

Market Outlook

Short Term

< 1 year
Cautious
Model confidence: 6/10

Key Factors

  • Price approaching resistance with bearish MACD signal
  • DCF valuation far below market price
  • High debt-to-equity ratio increasing financial risk

Medium Term

1–3 years
Neutral
Model confidence: 7/10

Key Factors

  • Stable free cash flow and solid operating margins
  • Potential acquisition interest from private‑equity firms
  • Improving earnings outlook and reaffirmed guidance

Long Term

> 3 years
Positive
Model confidence: 8/10

Key Factors

  • Strong brand portfolio with global reach
  • Long‑term cash generation capability despite leverage
  • Possible strategic transaction that could unlock value

Key Metrics & Analysis

Financial Health

Revenue Growth-4.10%
Profit Margin3.70%
P/E Ratio32.9
ROE17.88%
ROA8.72%
Debt/Equity539.65
P/B Ratio15.6
Op. Cash Flow$483.0M
Free Cash Flow$365.6M

Technical Analysis

TrendBullish
RSI65.0
Support$16.05
Resistance$18.16
MA 20$17.30
MA 50$15.93
MA 200$15.87
MACDBearish
VolumeIncreasing
Fear & Greed Index91.8

Valuation

Fair Value$3.05
Target Price$17.53
Upside/Downside-3.12%
GradeOvervalued
TypeValue

Risk Assessment

Beta0.43
Volatility31.84%
Sector RiskLow
Reg. RiskMedium
Geo RiskMedium
Currency RiskMedium
Liquidity RiskLow

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.